An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine
To test whether inactivated influenza vaccines distributed during the 2003–2004 influenza season in the northern hemisphere were able to confer protection against the mismatched variant A/Fujian/411/2002 virus strain, we measured haemagglutination inhibiting (HI) antibodies in elderly subjects vacci...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2006-04, Vol.24 (16), p.3063-3065 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3065 |
|---|---|
| container_issue | 16 |
| container_start_page | 3063 |
| container_title | Vaccine |
| container_volume | 24 |
| creator | Giudice, Giuseppe Del Hilbert, Anne Katrin Bugarini, Roberto Minutello, Ada Popova, Olga Toneatto, Daniela Schoendorf, Ines Borkowski, Astrid Rappuoli, Rino Podda, Audino |
| description | To test whether inactivated influenza vaccines distributed during the 2003–2004 influenza season in the northern hemisphere were able to confer protection against the mismatched variant A/Fujian/411/2002 virus strain, we measured haemagglutination inhibiting (HI) antibodies in elderly subjects vaccinated with three inactivated vaccines against the homologous A/H3N2 vaccine strain (A/Panama) and against the mismatched A/Fujian strain. The results showed that, while 76 to 80% of elder people vaccinated with conventional vaccines had protected levels of antibodies against the A/Fujian heterovariant strain, those vaccinated with the MF59-adjuvanted vaccine have protective levels of antibodies in >98% of the cases. We conclude that MF59-adjuvanted vaccines confer protection also against influenza virus strains which are not fully matched with those included in the vaccine. |
| doi_str_mv | 10.1016/j.vaccine.2006.01.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67810814</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X06000272</els_id><sourcerecordid>67810814</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-863f37ab0212282bdfa250ae62ce60181b905d8350d00adb131b5b16df2186953</originalsourceid><addsrcrecordid>eNqFkl2L1DAUhoso7rr6E5SAKHrRmZy0ybRXMiyOK6wfFwrehdMknU3ppGPSDuif9a94xims6MVCIAk873s-s-wp8AVwUMtucUBjfHALwblacKAj72XnUK2KXEio7mfnXKgyL4F_O8sepdRxzmUB9cPsDFSpSin4efZrHdiHjaxztN10wDA6y3xAM_oDnt5tP7nwE9kcjpkhjOiDD1u2Xn7GgDtcQl3X7NVV8VG8JoWdDCmbOKB1kSUXh37YeoM928dhdOQ9BIZbMkkju3EjAQeMnoL_Hc7HKbE0RsIo0GbqCFhSrYKNN0h6lqZmCn5kGOzxt-_9-H-6j7MHLfbJPZnvi-zr5u2Xy6v8-tO795fr69xQH8a8UkVbrLDhAoSoRGNbFJKjU8I4xaGCpubSVoXklnO0DRTQyAaUbQVUqpbFRfby5Eslfp9cGvXOJ-P6HoMbpqTVqgJeQXknCCuAgv8Bn_8DdsMUAxWhQZYrIlRVECVPlIlDStG1eh_9DuMPDVwfF0V3em6FPi6K5kDnmO-z2X1qds7equbNIODFDGCi0bURg_HpllsppTiviXtz4hx19-Bd1Ml4F2gDfKRRazv4O1L5DRBE38E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1547143683</pqid></control><display><type>article</type><title>An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Giudice, Giuseppe Del ; Hilbert, Anne Katrin ; Bugarini, Roberto ; Minutello, Ada ; Popova, Olga ; Toneatto, Daniela ; Schoendorf, Ines ; Borkowski, Astrid ; Rappuoli, Rino ; Podda, Audino</creator><creatorcontrib>Giudice, Giuseppe Del ; Hilbert, Anne Katrin ; Bugarini, Roberto ; Minutello, Ada ; Popova, Olga ; Toneatto, Daniela ; Schoendorf, Ines ; Borkowski, Astrid ; Rappuoli, Rino ; Podda, Audino</creatorcontrib><description>To test whether inactivated influenza vaccines distributed during the 2003–2004 influenza season in the northern hemisphere were able to confer protection against the mismatched variant A/Fujian/411/2002 virus strain, we measured haemagglutination inhibiting (HI) antibodies in elderly subjects vaccinated with three inactivated vaccines against the homologous A/H3N2 vaccine strain (A/Panama) and against the mismatched A/Fujian strain. The results showed that, while 76 to 80% of elder people vaccinated with conventional vaccines had protected levels of antibodies against the A/Fujian heterovariant strain, those vaccinated with the MF59-adjuvanted vaccine have protective levels of antibodies in >98% of the cases. We conclude that MF59-adjuvanted vaccines confer protection also against influenza virus strains which are not fully matched with those included in the vaccine.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2006.01.015</identifier><identifier>PMID: 16464520</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adjuvant ; Adjuvants, Immunologic ; Aged ; Aged, 80 and over ; Antibodies, Viral - blood ; Applied microbiology ; Avian flu ; Biological and medical sciences ; Confidence intervals ; Female ; Fundamental and applied biological sciences. Psychology ; Hemagglutination Inhibition Tests ; Heterovariant ; Humans ; Influenza ; Influenza A virus ; Influenza A virus - immunology ; Influenza A Virus, H3N2 Subtype - immunology ; Influenza Vaccines - administration & dosage ; Influenza Vaccines - immunology ; Male ; Microbiology ; Middle Aged ; Miscellaneous ; Older people ; Polysorbates ; Squalene - immunology ; Vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Inactivated - administration & dosage ; Vaccines, Inactivated - immunology ; Vaccines, Subunit - administration & dosage ; Vaccines, Subunit - immunology ; Virology</subject><ispartof>Vaccine, 2006-04, Vol.24 (16), p.3063-3065</ispartof><rights>2006 Elsevier Ltd</rights><rights>2006 INIST-CNRS</rights><rights>Copyright Elsevier Limited Apr 12, 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-863f37ab0212282bdfa250ae62ce60181b905d8350d00adb131b5b16df2186953</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X06000272$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17666009$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16464520$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giudice, Giuseppe Del</creatorcontrib><creatorcontrib>Hilbert, Anne Katrin</creatorcontrib><creatorcontrib>Bugarini, Roberto</creatorcontrib><creatorcontrib>Minutello, Ada</creatorcontrib><creatorcontrib>Popova, Olga</creatorcontrib><creatorcontrib>Toneatto, Daniela</creatorcontrib><creatorcontrib>Schoendorf, Ines</creatorcontrib><creatorcontrib>Borkowski, Astrid</creatorcontrib><creatorcontrib>Rappuoli, Rino</creatorcontrib><creatorcontrib>Podda, Audino</creatorcontrib><title>An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>To test whether inactivated influenza vaccines distributed during the 2003–2004 influenza season in the northern hemisphere were able to confer protection against the mismatched variant A/Fujian/411/2002 virus strain, we measured haemagglutination inhibiting (HI) antibodies in elderly subjects vaccinated with three inactivated vaccines against the homologous A/H3N2 vaccine strain (A/Panama) and against the mismatched A/Fujian strain. The results showed that, while 76 to 80% of elder people vaccinated with conventional vaccines had protected levels of antibodies against the A/Fujian heterovariant strain, those vaccinated with the MF59-adjuvanted vaccine have protective levels of antibodies in >98% of the cases. We conclude that MF59-adjuvanted vaccines confer protection also against influenza virus strains which are not fully matched with those included in the vaccine.</description><subject>Adjuvant</subject><subject>Adjuvants, Immunologic</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Viral - blood</subject><subject>Applied microbiology</subject><subject>Avian flu</subject><subject>Biological and medical sciences</subject><subject>Confidence intervals</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hemagglutination Inhibition Tests</subject><subject>Heterovariant</subject><subject>Humans</subject><subject>Influenza</subject><subject>Influenza A virus</subject><subject>Influenza A virus - immunology</subject><subject>Influenza A Virus, H3N2 Subtype - immunology</subject><subject>Influenza Vaccines - administration & dosage</subject><subject>Influenza Vaccines - immunology</subject><subject>Male</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Older people</subject><subject>Polysorbates</subject><subject>Squalene - immunology</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Inactivated - administration & dosage</subject><subject>Vaccines, Inactivated - immunology</subject><subject>Vaccines, Subunit - administration & dosage</subject><subject>Vaccines, Subunit - immunology</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkl2L1DAUhoso7rr6E5SAKHrRmZy0ybRXMiyOK6wfFwrehdMknU3ppGPSDuif9a94xims6MVCIAk873s-s-wp8AVwUMtucUBjfHALwblacKAj72XnUK2KXEio7mfnXKgyL4F_O8sepdRxzmUB9cPsDFSpSin4efZrHdiHjaxztN10wDA6y3xAM_oDnt5tP7nwE9kcjpkhjOiDD1u2Xn7GgDtcQl3X7NVV8VG8JoWdDCmbOKB1kSUXh37YeoM928dhdOQ9BIZbMkkju3EjAQeMnoL_Hc7HKbE0RsIo0GbqCFhSrYKNN0h6lqZmCn5kGOzxt-_9-H-6j7MHLfbJPZnvi-zr5u2Xy6v8-tO795fr69xQH8a8UkVbrLDhAoSoRGNbFJKjU8I4xaGCpubSVoXklnO0DRTQyAaUbQVUqpbFRfby5Eslfp9cGvXOJ-P6HoMbpqTVqgJeQXknCCuAgv8Bn_8DdsMUAxWhQZYrIlRVECVPlIlDStG1eh_9DuMPDVwfF0V3em6FPi6K5kDnmO-z2X1qds7equbNIODFDGCi0bURg_HpllsppTiviXtz4hx19-Bd1Ml4F2gDfKRRazv4O1L5DRBE38E</recordid><startdate>20060412</startdate><enddate>20060412</enddate><creator>Giudice, Giuseppe Del</creator><creator>Hilbert, Anne Katrin</creator><creator>Bugarini, Roberto</creator><creator>Minutello, Ada</creator><creator>Popova, Olga</creator><creator>Toneatto, Daniela</creator><creator>Schoendorf, Ines</creator><creator>Borkowski, Astrid</creator><creator>Rappuoli, Rino</creator><creator>Podda, Audino</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20060412</creationdate><title>An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine</title><author>Giudice, Giuseppe Del ; Hilbert, Anne Katrin ; Bugarini, Roberto ; Minutello, Ada ; Popova, Olga ; Toneatto, Daniela ; Schoendorf, Ines ; Borkowski, Astrid ; Rappuoli, Rino ; Podda, Audino</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-863f37ab0212282bdfa250ae62ce60181b905d8350d00adb131b5b16df2186953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adjuvant</topic><topic>Adjuvants, Immunologic</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Viral - blood</topic><topic>Applied microbiology</topic><topic>Avian flu</topic><topic>Biological and medical sciences</topic><topic>Confidence intervals</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hemagglutination Inhibition Tests</topic><topic>Heterovariant</topic><topic>Humans</topic><topic>Influenza</topic><topic>Influenza A virus</topic><topic>Influenza A virus - immunology</topic><topic>Influenza A Virus, H3N2 Subtype - immunology</topic><topic>Influenza Vaccines - administration & dosage</topic><topic>Influenza Vaccines - immunology</topic><topic>Male</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Older people</topic><topic>Polysorbates</topic><topic>Squalene - immunology</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Inactivated - administration & dosage</topic><topic>Vaccines, Inactivated - immunology</topic><topic>Vaccines, Subunit - administration & dosage</topic><topic>Vaccines, Subunit - immunology</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giudice, Giuseppe Del</creatorcontrib><creatorcontrib>Hilbert, Anne Katrin</creatorcontrib><creatorcontrib>Bugarini, Roberto</creatorcontrib><creatorcontrib>Minutello, Ada</creatorcontrib><creatorcontrib>Popova, Olga</creatorcontrib><creatorcontrib>Toneatto, Daniela</creatorcontrib><creatorcontrib>Schoendorf, Ines</creatorcontrib><creatorcontrib>Borkowski, Astrid</creatorcontrib><creatorcontrib>Rappuoli, Rino</creatorcontrib><creatorcontrib>Podda, Audino</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giudice, Giuseppe Del</au><au>Hilbert, Anne Katrin</au><au>Bugarini, Roberto</au><au>Minutello, Ada</au><au>Popova, Olga</au><au>Toneatto, Daniela</au><au>Schoendorf, Ines</au><au>Borkowski, Astrid</au><au>Rappuoli, Rino</au><au>Podda, Audino</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2006-04-12</date><risdate>2006</risdate><volume>24</volume><issue>16</issue><spage>3063</spage><epage>3065</epage><pages>3063-3065</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>To test whether inactivated influenza vaccines distributed during the 2003–2004 influenza season in the northern hemisphere were able to confer protection against the mismatched variant A/Fujian/411/2002 virus strain, we measured haemagglutination inhibiting (HI) antibodies in elderly subjects vaccinated with three inactivated vaccines against the homologous A/H3N2 vaccine strain (A/Panama) and against the mismatched A/Fujian strain. The results showed that, while 76 to 80% of elder people vaccinated with conventional vaccines had protected levels of antibodies against the A/Fujian heterovariant strain, those vaccinated with the MF59-adjuvanted vaccine have protective levels of antibodies in >98% of the cases. We conclude that MF59-adjuvanted vaccines confer protection also against influenza virus strains which are not fully matched with those included in the vaccine.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>16464520</pmid><doi>10.1016/j.vaccine.2006.01.015</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2006-04, Vol.24 (16), p.3063-3065 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67810814 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adjuvant Adjuvants, Immunologic Aged Aged, 80 and over Antibodies, Viral - blood Applied microbiology Avian flu Biological and medical sciences Confidence intervals Female Fundamental and applied biological sciences. Psychology Hemagglutination Inhibition Tests Heterovariant Humans Influenza Influenza A virus Influenza A virus - immunology Influenza A Virus, H3N2 Subtype - immunology Influenza Vaccines - administration & dosage Influenza Vaccines - immunology Male Microbiology Middle Aged Miscellaneous Older people Polysorbates Squalene - immunology Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Inactivated - administration & dosage Vaccines, Inactivated - immunology Vaccines, Subunit - administration & dosage Vaccines, Subunit - immunology Virology |
| title | An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T06%3A05%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20MF59-adjuvanted%20inactivated%20influenza%20vaccine%20containing%20A/Panama/1999%20(H3N2)%20induced%20broader%20serological%20protection%20against%20heterovariant%20influenza%20virus%20strain%20A/Fujian/2002%20than%20a%20subunit%20and%20a%20split%20influenza%20vaccine&rft.jtitle=Vaccine&rft.au=Giudice,%20Giuseppe%20Del&rft.date=2006-04-12&rft.volume=24&rft.issue=16&rft.spage=3063&rft.epage=3065&rft.pages=3063-3065&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2006.01.015&rft_dat=%3Cproquest_cross%3E67810814%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1547143683&rft_id=info:pmid/16464520&rft_els_id=S0264410X06000272&rfr_iscdi=true |